搜尋
Korro Bio Inc
KRRO添加自選
12.050USD
-0.840-6.52%
收盤 05/08, 16:00（美東）報價延遲15分鐘
173.79M總市值
虧損本益比TTM
關於 Korro Bio Inc 公司
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Korro Bio Inc簡介
公司代碼KRRO
公司名稱Korro Bio Inc
上市日期Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
員工數量104
證券類型Ordinary Share
年結日Oct 03
公司地址One Kendall Square. Building 600-700
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02139
電話16174681999
網址https://www.korrobio.com/
公司代碼KRRO
上市日期Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Korro Bio Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Pearson
Mr. Timothy R. Pearson
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
收入明細
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
United States
6.39M
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 8 小時前
更新時間: 8 小時前
持股股東
股東類型
持股股東
持股股東
佔比
Lynx1 Capital Advisors LLC
10.67%
New Enterprise Associates (NEA)
9.00%
Atlas Venture
7.88%
VR Adviser, LLC
7.00%
Point72 Asset Management, L.P.
5.66%
其他
59.79%
持股股東
持股股東
佔比
Lynx1 Capital Advisors LLC
10.67%
New Enterprise Associates (NEA)
9.00%
Atlas Venture
7.88%
VR Adviser, LLC
7.00%
Point72 Asset Management, L.P.
5.66%
其他
59.79%
股東類型
持股股東
佔比
Investment Advisor
36.98%
Venture Capital
24.28%
Hedge Fund
13.54%
Investment Advisor/Hedge Fund
4.01%
Research Firm
3.19%
Individual Investor
0.56%
Bank and Trust
0.07%
Pension Fund
0.05%
其他
17.33%
機構持股
更新時間: 4月1日 週三
更新時間: 4月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
215
11.84M
86.30%
+782.64K
2025Q4
193
11.05M
117.36%
+1.14M
2025Q3
186
9.33M
99.33%
-1.07M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Lynx1 Capital Advisors LLC
677.91K
4.7%
+677.91K
--
Dec 31, 2025
New Enterprise Associates (NEA)
1.30M
9%
+207.10K
+18.99%
Mar 10, 2026
Atlas Venture
1.14M
7.88%
--
--
Dec 31, 2025
VR Adviser, LLC
1.01M
7%
+1.01M
--
Mar 10, 2026
Point72 Asset Management, L.P.
816.88K
5.66%
+816.88K
--
Mar 10, 2026
Nantahala Capital Management, LLC
600.00K
4.16%
+600.00K
--
Dec 31, 2025
Vanguard Investments Australia Ltd.
489.64K
3.39%
+489.64K
--
Dec 31, 2025
The Vanguard Group, Inc.
489.64K
3.39%
+93.98K
+23.75%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
419.30K
2.91%
+10.58K
+2.59%
Dec 31, 2025
TCG Crossover Management, LLC
416.30K
2.89%
--
--
Dec 31, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.05%
Avantis US Small Cap Equity ETF
佔比0.02%
Global X Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares UltraPro Russell2000
佔比0%
SPDR Portfolio MSCI Global Stock Market ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
iShares Russell 3000 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
公告日期
除權除息日
類型
比率
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
